Business Context and Reporting Period
This Form 8-K is a current report filed by Synta Pharmaceuticals Corp. on April 22, 2016, regarding an event that occurred on April 19, 2016. The filing addresses the termination of a material definitive agreement concerning the company's principal executive offices located at 45 Hartwell Avenue, Lexington, MA.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The only specific financial figure disclosed relates to the lease termination:
- Final Termination Payment: $213,017.49 payable to the landlord, Duffy Hartwell, LLC.
Material Changes
The primary material change reported is the early termination of a lease agreement originally dated November 4, 1996, which was scheduled to expire on November 30, 2016. Key details include:
- Property: 34,250 square feet at 45 Hartwell Avenue, Lexington, MA.
- Termination Conditions: The lease terminates effective upon the company vacating the premises and the landlord receiving the final payment, both required to occur prior to May 1, 2016.
- Future Obligations: Following the termination date, the company will have no further rent obligations under this specific lease.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. The document focuses solely on the execution of the Lease Termination Agreement. No specific risks or contingencies beyond the completion of the vacating and payment requirements are detailed in the text.
Investor Verification Checklist
- Verify the company's new lease arrangements or relocation plans following the vacating of the Lexington, MA premises.
- Confirm the actual date the premises were vacated and the final payment was made to ensure the termination was effective before May 1, 2016.
- Review the attached Exhibit 10.1 (Lease Termination Agreement) for any additional covenants or conditions not summarized in the 8-K text.
- Note that the filing metadata provided in the request mentions "MADRIGAL PHARMACEUTICALS, INC.", but the filing text explicitly identifies the registrant as "SYNTA PHARMACEUTICALS CORP." Investors should verify the correct entity associated with this transaction.